Login / Signup

Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.

Jeroen V KoomenJasper StevensGeorge L BakrisRicardo Correa-RotterFan Fan HouDalane W KitzmanDonald KohanHirofumi MakinoJohn Joseph Valentine McMurrayHans-Henrik ParvingVlado PerkovicSheldon W TobeDick de ZeeuwHiddo J Lambers Heerspink
Published in: Diabetes, obesity & metabolism (2020)
Atrasentan plasma exposure varied among individual patients and partially explained between-patient variability in efficacy and safety response.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • clinical trial
  • prognostic factors
  • study protocol
  • randomized controlled trial
  • open label